Vivani Medical, a biopharmaceutical company specializing in miniaturized, ultra long-acting drug implants, will be showcasing its innovations in drug delivery at two upcoming conferences in October 2024.
Vivani Medical will participate in the Partnership Opportunities in Drug Delivery (PODD) event in Boston and the ThinkEquity Conference in New York.
At the PODD event, Vivani's CEO, Dr. Adam Mendelsohn, will join a panel discussion on targeted and long-acting delivery systems.
The ThinkEquity Conference will feature Dr. Mendelsohn presenting a company update.
Vivani Medical is leveraging its NanoPortal™ platform to develop biopharmaceutical implants that deliver drug molecules steadily over extended periods. This approach aims to enhance patient adherence and improve tolerance to medications, particularly for those managing chronic conditions such as obesity and Type 2 diabetes.
Vivani's lead program, NPM-115, features a miniature, six-month subdermal GLP-1 (exenatide) implant designed for chronic weight management. In addition to NPM-115, Vivani is advancing its NPM-139 program, which focuses on a semaglutide implant for chronic weight management. The NPM-119 program targets Type 2 diabetes with a similar six-month exenatide implant.
Vivani's innovative implants aim to provide a more consistent and reliable method of drug delivery, thereby enhancing the overall effectiveness of treatment for patients with chronic diseases. By reducing the frequency of administration, these implants can help alleviate the burden of daily medication routines, which often lead to missed doses and suboptimal treatment results.
Despite the highly competitive landscape for GLP-1 therapies, Vivani Medical is confident that its differentiated portfolio of miniature long-acting GLP-1 implants will offer a compelling therapeutic option. The company's focus on developing implants that can be administered less frequently than traditional oral or injectable medications positions it favorably in the market.
As Vivani Medical prepares for its presentations at the PODD and ThinkEquity conferences, the biopharmaceutical community will be closely watching the company's progress. The insights shared by Dr. Mendelsohn and other industry leaders will likely shed light on the future of drug delivery systems and their potential to transform the management of chronic conditions. With a strong focus on innovation and patient-centric solutions, Vivani is poised to make a significant impact in the biopharmaceutical landscape.